If so, ERK5 inhibitors might be relevant for improving the efficacy of NK-based immunotherapies, since NK cells switch from granzyme/perforin-mediated cancer cell death to TRAIL/FasL-induced cytotoxicity during subsequent tumor cell encounters (also called serial killing) [40]. Here, PRF1 is linked to neoplasm.